In collaboration with Kyoto Prefectural University of Medicine, Takara Bio studies NK (natural killer) cells induced by RetroNectin for cancer immunotherapy. At the 12th Annual Meeting of the Japan Society of Clinical Oncology, a collaborating group from Mie University School of Medicine reported that 3 out of 10 patients had shown long-term survival rates.

Takara Bio news release, February 22, 2014; Nikkei Biotech news release, July 22, 2014